国家重点研发计划骨干

国家自然科学基金面上项目、青年项目负责人

北京自然科学基金青年项目负责人

北京市医管中心扬帆计划负责人

1.        Yan B, Lou H, Wang Y, Li Y, Meng Y, Qi S, Wang M, Xiao L, Wang C*, Zhang L*. Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(2):455-469.

2.        Wu D#, Yan B#, Wang Y, Wang C*, Zhang L*. Prognostic and pharmacologic value of cystatin SN for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2021. 148(2):450-460.

3.        Wu D#, Yan B#, Wang Y, Zhang L*, Wang C*. Charcot-Leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(1):345-348.e8.

4.        Yan B, Wang Y, Li Y, Wang C*, Zhang L*. Inhibition of arachidonate 15-lipoxygenase reduces the epithelial-mesenchymal transition in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2019;9(3):270-280.

5.        Meng Y#, Yan B#, Wang Y, Wu D, Zhang L*, Wang C*. Diagnosis and management of nonallergic rhinitis with eosinophilia syndrome using cystatin SN together with symptoms. World Allergy Organ J. 2020;17;13(7):100134.

6.        Qi S#, Yan B#, Liu C, Wang C*, Zhang L*. Predictive significance of Charcot-Leyden Crystal mRNA levels in nasal brushing for nasal polyp recurrence. Rhinology. 2020;58(2):166-174.

7.        Liang Z#, Yan B#, Liu C, Tan R, Wang C*, Zhang L*. Predictive significance of arachidonate 15-lipoxygenase for eosinophilic chronic rhinosinusitis with nasal polyps. Allergy Asthma Clin Immunol. 2020;16:82.

8.        Wu D#, Yan B#, Wang Y, Zhang L*, Wang C*. Predictive significance of Charcot-Leyden Crystal protein in nasal secretions in recurrent chronic rhinosinusitis with nasal polyps. Int Arch Allergy Immunol. 2021;182(1):65-75.

9.        Zhang M#, Yan B#, Wang Y, Wang C*, Zhang L*. Charcot-Leyden Crystal Protein in nasal secretions of patients with nonallergic rhinitis with eosinophilia syndrome. Int Arch Allergy Immunol. 2020;181(11):888-896.

10.    Liu C#, Yan B#, Qi S, Zhang Y, Zhang L*, Wang C*. Predictive significance of Charcot-Leyden Crystals for eosinophilic chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2019;33(6):671-680.

11.    Wang C, Yan B*, Zhang L*. The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2020;16(3):293-310.

12.    Yan B, Wang C, Zhang L. Cystatin SN-more than a type 2 immunity marker. J Allergy Clin Immunol. 2023 Jan;151(1):287-288.

13.    Yan B, Ren Y, Liu C, Shu L, Wang C, Zhang L. Cystatin SN in type 2 inflammatory airway diseases. J Allergy Clin Immunol. 2023 May;151(5):1191-1203.e3.

14.    Zhang Y#, Yan B#, Shen S#, Song X, Jiang Y, Shi L, Zhao C, Yang Y, Jiang L, Li J, Ye J, Liu J, Wan L, Yang Y, Chen J, Liu F, Su L, Xu Y, Tan G, Yu S, Zhang Y, Wang L, Liu S, Yan H, Liu W, Chen B, Wang C*, Zhang L*. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5;61:102076.

15.     Yan B, Zhang L. Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge. Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):827-830. doi: 10.1080/1744666X.2023.2207822.

16.      IgE directly affects eosinophil migration in CRSwNP through CCR3 and predicts the efficacy of omalizumab. J Allergy Clin Immunol. 2023  (Accepted)